Manufacturing and processing challenges surrounding mRNA can be overcome in order to realize the true potential of a technology 30 years in the making.
Scott Ripley
Advertisement
Scott Ripley is the general manager, nucleic acid, for Cytiva.
Articles by Scott Ripley
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
New Cellevate Nanofiber Microcarriers Aim to Transform Vaccine Manufacturing Processes
2
In KPMG's CEO Outlook, AI, Regulatory Demands, and Supply Chain Risk Rank High
3
Overcoming Funding Challenges and Maintaining Optimism in CGTs (Part 1)
4
Rentschler’s Time Capsule and How it Symbolizes European Biotech Progress
5
